TY  - JOUR
T1  - AMid lingering questions, fda reprieves ldl cholesterol–lowering medication
AU  - Mitka M
Y1  - 2009/02/25
N1  - 10.1001/jama.2009.196
JO  - JAMA
SP  - 813
EP  - 815
VL  - 301
IS  - 8
N2  - 
The agency's review of ezetimibe/simvastatin was prompted when the drug combination's efficacy was questioned based on data released in March 2008 from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. The study's investigators concluded that the relatively expensive proprietary drug produced greater reductions in levels of LDL-C than did simvastatin alone but resulted in similar changes in arterial intima-media thickness, a surrogate measurement for atherosclerosis progression, a risk factor for cardiovascular disease (Kastelein JJP et al. N Engl J Med. 2008;358[14]:1431-1443).

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.196
UR  - http://dx.doi.org/10.1001/jama.2009.196
ER  -